European Pharmaceutical Review

AUGUST 15, 2023

billion by 2030, according to a report from Data Bridge Market Research. This represents a compound annual growth rate (CAGR) of close to 10 percent. According to the report buccal delivery is the “most feasible and preferred choice compared to oral dosage forms, particularly among elderly patients.” billion in 2023 to $7.13

Dosage 52

Dosage Compounding 52

European Pharmaceutical Review

OCTOBER 7, 2022

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 billion by 2030, displaying a compound annual growth rate (CAGR) of 6.0 Leading companies in the oral solid dosage market are Catalent, Inc.,

Dosage 82

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 82

European Pharmaceutical Review

FEBRUARY 3, 2023

The facility forms two new fully-automated production lines for liquid and freeze-dried drugs, including highly potent compounds and advanced therapies such as antibody drug conjugates (ADCs). The HPAPI market A 2022 market report showed that due to the small volumes required for dosage, small-scale providers are also gaining importance.

Dosage 90

Dosage Compounding Pharmaceutical Companies Pharmaceutical Companies 90

Express Pharma

NOVEMBER 28, 2023

Over-the-counter accessibility and limited awareness compound the problem. It is crucial to find a delicate balance in antibiotic dosages, acknowledging that overuse contributes to resistance. Over-the-counter accessibility and limited awareness compound the problem.

Hospitals 86

Hospitals Dosage Compounding Communication 86